GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » EPS without NRI

Cingulate (Cingulate) EPS without NRI : $-23.94 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cingulate EPS without NRI?

Cingulate's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.60. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.94.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cingulate's EPS without NRI or its related term are showing as below:

CING' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27   Med: -19.95   Max: -12.9
Current: -27

During the past 5 years, Cingulate's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -12.90% per year. The lowest was -27.00% per year. And the median was -19.95% per year.

CING's 3-Year EPS without NRI Growth Rate is ranked worse than
81.88% of 1297 companies
in the Biotechnology industry
Industry Median: 5.5 vs CING: -27.00

Cingulate's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.60. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.94.

Cingulate's EPS (Basic) for the three months ended in Mar. 2024 was $-0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.94.


Cingulate EPS without NRI Historical Data

The historical data trend for Cingulate's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate EPS without NRI Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-20.42 -12.70 -55.80 -29.35 -26.00

Cingulate Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.08 -11.40 -6.00 -5.94 -0.60

Competitive Comparison of Cingulate's EPS without NRI

For the Biotechnology subindustry, Cingulate's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cingulate's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cingulate's PE Ratio without NRI falls into.



Cingulate EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cingulate  (NAS:CING) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cingulate EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cingulate's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cingulate (Cingulate) Business Description

Traded in Other Exchanges
N/A
Address
1901 W. 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Executives
Jennifer L. Callahan officer: Corporate Controller C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth director, 10 percent owner C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer director, 10 percent owner, officer: Chief Executive Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon officer: EVP & General Counsel C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers officer: EVP & Chief Operating Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum director C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros director 2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G officer: EVP & Chief Financial Officer C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy director 2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva officer: EVP & Chief Science Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams officer: EVP & Chief Medical Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc 10 percent owner 1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205